ReviewAnaerobe2016
Structural and functional changes within the gut microbiota and susceptibility to Clostridium difficile infection.
Review in Anaerobe, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Re-establishing bile acid composition after treatment of recurrentGut microbes · 2026Trial
- Characterization of the Gut Microbiome of Patients withPathogens (Basel, Switzerland) · 2026Article
- Metagenomic analysis reveals distinct patterns of gut microbiota features with diversified functions inGut microbes · 2025Article
- Fecal Metabolomics for the Diagnosis ofDiagnostics (Basel, Switzerland) · 2025Article
- Lactiplantibacillus plantarum GMNL-661 Ameliorates Clostridioides difficile Infection and Reconfigures Intestinal Microbiota in a Murine Model.Probiotics and antimicrobial proteins · 2025Article
- Gut Microbiota and New Microbiome-Targeted Drugs forAntibiotics (Basel, Switzerland) · 2024Review
- Fecal Microbiota Transplantation for RecurrentMicroorganisms · 2024Article
- Role of N-acetylkynurenine in mediating the effect of gut microbiota on urinary tract infection: a Mendelian randomization study.Frontiers in microbiology · 2024Article
- Network analysis of toxin production in Clostridioides difficile identifies key metabolic dependencies.PLoS computational biology · 2023Article
- Synthetic microbial communities (SynComs) of the human gut: design, assembly, and applications.FEMS microbiology reviews · 2023Article
- Article
- Diarrheal-associated gut dysbiosis in cancer and inflammatory bowel disease patients is exacerbated byFrontiers in cellular and infection microbiology · 2023Article
- Gut Microbiota Composition Associated withPathogens (Basel, Switzerland) · 2022Review
- Microbial metabolites: cause or consequence in gastrointestinal disease?American journal of physiology. Gastrointestinal and liver physiology · 2022Review
- Effects of Intravenous Antimicrobial Drugs on the Equine Fecal Microbiome.Animals : an open access journal from MDPI · 2022Article
- The impact of dietary fibers onFrontiers in cellular and infection microbiology · 2022Article
- Gut Microbiota and Metabolite Changes in Patients With Ulcerative Colitis andFrontiers in microbiology · 2022Article
- Management and characteristics of patients suffering fromThe European journal of general practice · 2021Observational
- Targeting the gut to treat multiple sclerosis.The Journal of clinical investigation · 2021Review
- Gut Dysbiosis andFrontiers in microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Alteration of the gut microbial community structure and function through antibiotic use increases susceptibility to colonization by Clostridium difficile and other enteric pathogens. However, the mechanisms that mediate colonization resistance remain elusive. As the leading definable cause of infectious diarrhea, toxigenic C. difficile represents a burden for patients and health care systems, underscoring the need for better diagnostics and treatment strategies. Next-generation sequence data has increased our understanding of how the gut microbiota is influenced by many factors including diet, disease, aging and drugs. However, a microbial-based biomarker differentiating C. difficile infection from antibiotic-associated diarrhea has not been identified. Metabolomics profiling, which is highly responsive to changes in physiological conditions, have shown promise in differentiating subtle disease phenotypes that exhibit a nearly identical microbiome community structure, suggesting metabolite-based biomarkers may be an ideal diagnostic for identifying patients with CDI. This review focuses on the current understanding of structural and functional changes to the gut microbiota during C. difficile infection obtained from studies assessing the microbiome and metabolome of samples from patients and murine models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.